Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas
NCT03277209 · Weill Medical College of Cornell University · PHASE1 · terminated · last registry update 2020-03-02 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “terminated due to slow accrual” | Open Targets' class: insufficient enrollment | Registry record, Weill Medical College of Cornell University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR4 in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision